Single-use systems (SUS) have revolutionized biopharmaceutical manufacturing, with single-use bioreactors (SUBs) leading the charge in recent decades. However, while the adoption of SUBs has plateaued, other forms of single-use technology (SUT) are gaining momentum. The landscape is evolving
The bioprocessing sector, a critical component within the Life Sciences industry, continually faces hurdles in bringing innovative technologies from development to market. BioProcess360 Partners has introduced a novel investment fund aimed at bridging this gap. By providing both capital and
Optimizing cell line development (CLD) for next-generation biologics is crucial to meet the rapidly growing demand for novel therapeutic modalities. As the biologics sector evolves, it's imperative to address potential bottlenecks in the development process through strategic enhancements and
In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a
As environmental issues become ever more pressing, pharmaceutical giant Boehringer Ingelheim is leading a green revolution within its industry, with a special focus on sustainable vaccine production. The company's innovative initiatives extend well beyond the finished vaccine. Boehringer
Upstream bioprocessing is pivotal in biomanufacturing, where cellular systems produce vital therapeutic proteins and biological products. This field is experiencing a surge of innovative methods in response to the increased global demand for biopharmaceuticals driven by rising health concerns.
